ModifiedUnitedHealthcarePolicy CS015PA.R

Cardiovascular Disease Risk Tests (for Pennsylvania Only)

Policy governing use and coverage of various cardiovascular disease risk tests (e.g., arterial compliance, carotid intima-media thickness, advanced lipoprotein and multi-protein biomarker tests) for members in Pennsylvania.

Policy Summary

PayerUnitedHealthcare

PolicyCardiovascular Disease Risk Tests (for Pennsylvania Only)

Policy CodePolicy CS015PA.R

Change TypeMaterial updates: added CPT 0541Urevised unproven test list

Effective DateSep 1, 2025

Next Review DateN/A

Key ActionVerify benefit terms and obtain prior authorization when ordering newly listed or low‑evidence cardiovascular risk tests (e.g., CPT 0541U) as they may be denied or require justification.

SourceLink

POLICY UPDATE CHANGES

Added CPT code 0541U to the list of applicable codes.

Revised list of unproven and not medically necessary services to include an HDL reverse cholesterol transport/cholesterol efflux capacity LC-MS/MS panel reporting five distinct HDL-bound apolipoproteins as a risk score.

Updated Clinical Evidence and References sections to reflect the most current information.

Pennsylvania-onlystate-specific application

>= 9listed as unproven / not medically necessary

multipleapplicable procedure codes provided

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

thresholdsLp(a) risk categories reported

0541Unewly added code

Coverage Criteria and Evidence Summary

inv-01: Unproven / Not Medically Necessary

Tests considered unproven and not medically necessary due to insufficient evidence of efficacy include:

Unproven tests list: Arterial compliance testing using waveform analysis; Carotid intima-media thickness (CIMT) measurement as an effective screening tool for management of cardiovascular disease; Advanced lipoprotein analysis (including lipoprotein(a), subfractions, particle size, NMR, vertical auto profile); Lipoprotein-associated phospholipase A2 (Lp-PLA2); Endothelial function assessment using peripheral arterial tonometry (PAT) or brachial artery ultrasound; Multi-protein diagnostic biomarker panels (aptamer-based microarray with algorithm; LC-MS/MS cholesterol efflux capacity measurement of 5 distinct HDL-bound apolipoproteins with algorithm; 3-protein panel: hs-troponin, adiponectin, KIM-1 with algorithm; 4-protein panel: NT-proBNP, osteopontin, TIMP-1, KIM-1 with algorithm; 7-protein panel: IL-16, FAS, FASLigand, HGF, CTACK, EOTAXIN, MCP-3 with algorithm)

Listed as unproven and not medically necessary due to insufficient evidence that these tests alter management or improve outcomes.

inv-02: Coverage-relevant evidence summary

Summary of evidence-based findings relevant to coverage decisions:

CIMT is associated with future CVD events and stroke in multiple studies and meta-analyses, but heterogeneity of measurement methods, modest incremental predictive value beyond traditional risk factors, and lack of evidence that routine CIMT measurement changes clinical management or improves outcomes limit its clinical utility.

See Den Ruijter 2012, Azcui Aparicio 2021, Willeit 2020; heterogeneity and small net reclassification gains noted.

Advanced lipoprotein testing (apoB, Lp-PLA2, others): Available studies report inconsistent or low-quality evidence for incremental benefit of advanced lipoprotein tests over conventional lipid measures; lack of standardization and patient selection criteria limit demonstrated clinical utility for changing management.

Emerging Risk Factors Collaboration and other cohort analyses found minimal improvement when replacing total cholesterol and HDL-C with other lipid parameters.

Lipoprotein(a) [Lp(a)]: Lp(a) is consistently associated with increased CVD events across large cohorts and pooled analyses, and high percentiles or thresholds (e.g., ≥50 mg/dL or ≥90th percentile) are linked to higher risk; however, evidence that measuring Lp(a) improves clinical decision-making or outcomes is not established in the cited studies.

See BiomarCaRE, ATTICA, and large retrospective cohorts showing elevated HRs for higher Lp(a) categories.

inv-03: Evidence-based coverage summary (qualitative)

Coverage stance summarized from evidence sections in this document portion:

Lp(a): Elevated Lp(a) is associated with increased risk of major coronary events and CVD in cohort analyses (notably levels ≥90th percentile), which may inform identification of populations for future therapies; evidence that measuring Lp(a) alters clinical outcomes is not provided here.Lp(a) >= 90th percentile associated with higher risk

BiomarCaRE pooled analyses and large cohorts document effect sizes.

Lp-PLA2: Multiple cohorts and meta-analyses report modest associations between higher Lp-PLA2 mass/activity and increased risk of stroke and CHD, but overall evidence quality is low and clinical utility as an adjunct risk marker is unestablished.higher Lp-PLA2 associated with relative risks up to ~1.5 in some analyses

Heterogeneous assays and populations limit conclusions.

Multi-protein algorithmic tests:

inv-04: Endothelial function tests (PAT, FMD) — evidence stance

Evidence for endothelial function testing (PAT, FMD) shows limited or inconsistent predictive utility:

Endothelial function testing evidence summary: Large cohort and smaller studies found that noninvasive measures of endothelial function (flow-mediated dilation, peripheral arterial tonometry/RHI) did not consistently predict incident CVD, coronary plaque severity, or major adverse cardiovascular events; overall, these measures have not demonstrated clinical utility for routine risk stratification or to change management.

Supported by Schnabel 2021, Venuraju 2019, Van den Heuvel 2015, and other correlation studies showing conflicting or non-predictive results.

inv-05: Guideline-based biomarker and imaging indications

Guideline recommendations for biomarker and imaging tests to refine ASCVD risk:

When Lp(a) measurement is indicated: Measure Lp(a) in selected situations: individuals with clinical ASCVD (especially premature or recurrent despite LDL-C lowering), family history of premature ASCVD or increased Lp(a), certain ancestries (e.g., South Asian, African), primary prevention patients with 10-year ASCVD risk ≥10% to refine risk, personal/family history of aortic valve stenosis, or refractory LDL-C despite therapy.

AACE 2020, AHA and NLA guidance support one-time measurement in specified contexts and define risk thresholds.

ApoB and advanced lipid testing indications: ApoB measurement is reasonable for people at increased ASCVD risk (e.g., diabetes, high triglycerides, obesity, metabolic syndrome); advanced lipoprotein testing (LDL-P, particle sizing) lacks standardization and should be reserved for select patients after initial lipid evaluation.apoB goals cited in guidelines (examples: <90 mg/dL, <80 mg/dL, <70 mg/dL depending on risk)

AACE 2017, NLA, and ESC/EAS statements provide context and recommended use in select patients.

Tests not recommended for routine risk assessment:

inv-06: Guideline-informed coverage considerations

Policy references guideline conclusions and records specific services as unproven/not medically necessary (revised):

Guideline context: USPSTF concluded evidence is insufficient to support ABI screening for PAD/CVD risk in asymptomatic adults; VA/DoD recommends against routine use of additional risk markers when assessing cardiovascular risk; policy revisions incorporate guideline conclusions and explicitly categorize specific novel tests (e.g., LC-MS/MS 5-apolipoprotein HDL efflux panel) as unproven and not medically necessary.

See USPSTF 2018, VA/DoD 2020, and policy revision dated 09/01/2025 adding the HDL efflux LC-MS/MS panel to the unproven list.

The tests listed below are considered unproven and not medically necessary because current evidence does not demonstrate that their use alters clinical management or improves patient outcomes: arterial compliance testing using waveform analysis; carotid intima-media thickness (CIMT) measurement for screening/management of cardiovascular disease; advanced lipoprotein analysis (including Lp(a), subfractions, or particle size); lipoprotein-associated phospholipase A2 (Lp-PLA2); endothelial function assessment (e.g., peripheral arterial tonometry or brachial artery ultrasound); and specified multi-protein diagnostic biomarker panels (including aptamer-based microarray algorithms and multi-apolipoprotein LC-MS/MS panels reported as a risk score).

No high-quality evidence demonstrates that Lp-PLA2, measured alone or combined with traditional biomarkers, reliably identifies CHD risk or changes management in asymptomatic individuals; therefore its clinical utility as an adjunct risk marker is unproven and may be considered not medically necessary outside of research settings.

Multi-protein algorithmic blood tests and noninvasive endothelial function assessments lack sufficient peer-reviewed evidence showing clinical utility. Although some cohort or proteomic studies report correlations or discriminatory statistics, these tests have not been shown to improve decision-making or patient outcomes and are considered insufficiently validated for routine clinical use.

Measures of arterial stiffness and peripheral endothelial function (e.g., pulse wave velocity, pulse wave analysis, flow-mediated dilation, peripheral arterial tonometry) and routine ankle-brachial index (ABI) screening in asymptomatic adults are not recommended for routine cardiovascular risk assessment or screening because guideline statements cite no proven benefit or insufficient evidence to support their routine use.

The revised list of unproven and not medically necessary services explicitly includes a specific HDL reverse cholesterol transport/cholesterol efflux capacity assay: LC-MS/MS quantitative measurement of five distinct HDL-bound apolipoproteins (A1, C1, C2, C3, C4) reported with an algorithm as a risk score, which is categorized as not medically necessary.

Arterial compliance testing (waveform analysis), CIMT used for screening or routine management, advanced lipoprotein analyses (including particle sizing/NMR/vertical auto profile), and Lp-PLA2 are listed as unproven or not medically necessary due to inconsistent evidence, lack of standardization, and absence of data showing improved outcomes when used to guide care.

Routine use of CIMT or Lp-PLA2 for risk assessment in asymptomatic individuals is discouraged when there is no clear plan for how results will change management; studies show only modest incremental predictive value for CIMT and low-quality evidence for Lp-PLA2, so testing without a management strategy is not supported.

Endothelial function testing (e.g., PAT-derived reactive hyperemia indices or brachial artery FMD) and multi-protein blood tests that report algorithmic risk scores have conflicting or limited associations with cardiovascular outcomes and do not demonstrate proven clinical effectiveness, and therefore lack sufficient evidence to support routine clinical use.

Peripheral arterial flow-mediated dilation and arterial stiffness assessments are not recommended outside research settings, and routine ABI screening in asymptomatic adults is not supported by current evidence; these modalities should not be used for routine population screening absent clear guideline-based indications.

The policy revision explicitly categorizes the HDL efflux LC‑MS/MS 5‑apolipoprotein panel (reported with an algorithmic risk score) as not medically necessary, and the coding table was updated to add CPT code 0541U referencing this assay.

Procedure, CPT, and Regulatory Codes

Named Proprietary/Unlisted Molecular/Protein Panel CodesCPT

0019M	Cardiovascular disease, plasma, analysis of protein biomarkers by aptamer-based microarray and algorithm reported as 4-year likelihood of coronary event in high-risk populations.
0052U	Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation.
0308U	Cardiology [coronary artery disease (CAD)], analysis of 3 proteins [high sensitivity (hs) troponin, adiponectin, and kidney injury molecule-1 (KIM-1)] with 3 clinical parameters (age, sex, history of cardiac intervention), plasma, algorithm reported as a risk score for obstructive CAD.
0309U	Cardiology (cardiovascular disease), analysis of 4 proteins [NT-proBNP, osteopontin, tissue inhibitor of metalloproteinase-1 (TIMP-1), and kidney injury molecule-1 (KIM-1)], plasma, algorithm reported as a risk score for major adverse cardiac event.
0377U	Cardiovascular disease, quantification of advanced serum or plasma lipoprotein profile, by nuclear magnetic resonance (NMR) spectrometry with report of a lipoprotein profile (including 23 variables).
0415U	Cardiovascular disease [acute coronary syndrome (ACS)], IL-16, FAS, FASLigand, HGF, CTACK, EOTAXIN, and MCP-3 by immunoassay combined with age, sex, family history, and personal history of diabetes, blood, algorithm reported as a 5-year (deleted risk) score for ACS.
0541U	Cardiovascular disease (HDL reverse cholesterol transport), cholesterol efflux capacity, LC-MS/MS, quantitative measurement of 5 distinct HDL-bound apolipoproteins (apolipoproteins A1, C1, C2, C3, and C4), serum, algorithm reported as prediction of coronary artery disease (pCAD) score.

Other Relevant CPT/HCPCS Codesmixed

83695	Lipoprotein (a).
83698	Lipoprotein-associated phospholipase A2 (Lp-PLA2).
83701	Lipoprotein, blood; high resolution fractionation and quantitation of lipoproteins including lipoprotein subclasses when performed (e.g., electrophoresis, ultracentrifugation).
83704	Lipoprotein, blood; quantitation of lipoprotein particle number(s) (e.g., by nuclear magnetic resonance spectroscopy), includes lipoprotein particle subclass(es), when performed.
93050	Arterial pressure waveform analysis for assessment of central arterial pressures includes obtaining waveform(s), digitization and application of nonlinear mathematical transformations to determine central arterial pressures and augmentation index, with interpretation and report, upper extremity artery, non-invasive.
93799	Unlisted cardiovascular service or procedure.
93895	Quantitative carotid intima media thickness and carotid atheroma evaluation, bilateral.
93998	Unlisted noninvasive vascular diagnostic study.

Added CPT codesCPT

0541U

LC-MS/MS quantitative measurement of 5 distinct HDL-bound apolipoproteins with algorithm reported as a risk score (newly added)

FDA product codes (informational)mixed

DXN	FDA product code for non-invasive blood pressure measurement systems (informational)
IYO	FDA product code for B-mode ultrasound equipment used to measure CIMT (informational)
DFC	FDA product code for Lp(a) measurement products (informational)
NOE	FDA product code for Lp-PLA2 measurement products (informational)
JJX	FDA product code for Lp-PLA2 measurement products (informational)

FDA 510(k) clearances (informational)mixed

K032519	EndoPAT 2000 510(k) clearance number (informational)
K001852	PAT 1000 RD predicate device 510(k) (informational)
K122129	SphygmoCor XCEL 510(k) clearance (informational)
K070795	SphygmoCor CVMS predicate device 510(k) (informational)

inv-22: cfPWV predictive cut-off (reported)

cfPWV predictive cut-off (reported)Approx. 10.7 - 11.5 m/s (closest cut-off points reported in pooled analysis of cfPWV for cardiovascular and all-cause mortality)

cfPWV evidence contextDerived from systematic review/meta-analysis of cfPWV studies (n=9; pooled dOR and HSROC reported)

Limitations notedAuthors reported publication bias, small sample size, and heterogeneity in measurement techniques; incremental clinical utility not reported

inv-23: Mean baseline CCA-IMT in pooled studies

Mean baseline CCA-IMT0.71 mm (overall mean of baseline common carotid artery IMT in meta-analysis of 21,494 individuals)

Provider Actions, Prior Authorization, and Documentation

Note

Case-by-case evaluation and applicability

This policy applies to Pennsylvania; requests for services not meeting criteria will be evaluated case-by-case and Pennsylvania exceptions (PA Code, Title 55, Chapter 1101) may apply.

Case-by-case evaluation for requests that do not meet PARP criteria
Refer to Pennsylvania Exceptions, PA Code, Title 55, Chapter 1101

Prior Authorization

Prior Authorization for Low-Evidence and Novel Tests

Tests and testing modalities with limited or low-quality evidence (for example, Lp-PLA2, multi-protein algorithmic blood tests, endothelial function assessments, arterial compliance testing, CIMT for screening/management) may require prior authorization. Prior auth ensures medical necessity, documentation of guideline-based indication, and verification of benefit terms.

Prior authorization may be required for newly listed or low-evidence tests (e.g., CPT 0541U)
Provide rationale for testing and any prior standard risk assessment results when requesting prior authorization

Background and Definitions

Cardiovascular diseases (CVD), including coronary artery disease, stroke, and hypertension, are leading causes of morbidity and mortality. A range of novel tests have been proposed to refine risk beyond traditional factors, but many — including arterial compliance measures, CIMT, advanced lipoprotein analyses, endothelial function testing, Lp-PLA2, and multi-protein biomarker panels — have not been shown to reliably improve clinical decision-making or outcomes and therefore should be used only when supported by guideline-based indications or research protocols.

inv-54: CIMT definition

Definition of CIMTCarotid intima-media thickness (CIMT) is a noninvasive ultrasound measurement of carotid artery wall thickness used as a surrogate marker of atherosclerosis and cardiovascular risk

Measurement contextCIMT uses B-mode ultrasound images with software analysis of carotid artery measurements (common carotid artery IMT commonly reported)

Clinical limitationsHeterogeneity in measurement methods and modest incremental predictive value beyond traditional risk factors limit routine clinical utility

inv-55: Arterial compliance / PWV / PWA

Policy Summary

PayerUnitedHealthcare

PolicyCardiovascular Disease Risk Tests (for Pennsylvania Only)

Policy CodePolicy CS015PA.R

Change TypeMaterial updates: added CPT 0541Urevised unproven test list

Effective DateSep 1, 2025

Next Review DateN/A

Key ActionVerify benefit terms and obtain prior authorization when ordering newly listed or low‑evidence cardiovascular risk tests (e.g., CPT 0541U) as they may be denied or require justification.

SourceLink

On This Page

Multi-protein blood tests with algorithmic risk scores show promising discrimination in selected cohorts (example C-statistic 0.77 in one study) but lack robust peer-reviewed clinical utility studies and external validation to demonstrate improved management or outcomes.

examples include reported C-statistic 0.77 in targeted cohort

Hayes evidence brief and Mohebi et al. study illustrate current evidence gaps.

Endothelial function assessment: Noninvasive endothelial function measures (PAT, flow-mediated dilation) show conflicting associations with CVD and do not demonstrate clinically relevant predictive utility for routine risk stratification in general or asymptomatic populations.studies with cohort sizes up to ~12,599 showed no clinically relevant association

Schnabel 2021 and other cohort studies failed to show routine utility.

Professional society guidance (ACC/AHA, USPSTF, VA/DoD) advises against routine use of peripheral endothelial measures (FMD), measures of arterial stiffness outside research settings, routine CIMT for general screening, and routine ABI screening in asymptomatic adults without indications.

ACC/AHA and USPSTF statements summarized in policy support limited use of these tests outside defined contexts.

Study contextPooled participant-level data from 20 prospective studies in the Proof-ATHERO consortium

Follow-upMedian follow-up 5.9 years; used to relate baseline CCA-IMT to incident carotid plaque

inv-24: CIMT cutoff evaluated for CAD diagnosis

CIMT cutoff evaluated for CAD diagnosis1 mm (cutoff value shown to be more accurate diagnostic criterion for CAD in pooled analysis)

Diagnostic performanceSensitivity ~0.66; specificity ~0.79; AUC ~0.80 for cutoff 1 mm

LimitationsSignificant heterogeneity across studies and unclear impact on clinical outcomes

inv-25: Lp(a) threshold used in ATTICA study

Lp(a) threshold used in ATTICA study50 mg/dL (recommended threshold to define abnormal Lp(a) status)

ATTICA cohort sizeBaseline Lp(a) measured in 1890 participants; follow-up CVD assessment in 2020 participants

Associated riskTen-year CVD-event rate 24% for Lp(a) ≥50 mg/dL vs 14% for <50 mg/dL (HR ≈2.18 after multivariate adjustment)

inv-26: Lp(a) percentile associated with higher events

Lp(a) percentile associated with higher events≥ 90th percentile (highest event rates for MCE and CVD observed at or above this percentile)

Pooled analysis contextBiomarCaRE project analysis of 56,804 participants showing HRs for MCE and CVD highest at >90th percentile

Effect sizesHR ~1.49 for major coronary events for >90th percentile vs lowest third

inv-27: Lp(a) thresholds

Lp(a) risk categories (nmol/L and mg/dL)< 75 nmol/L (≈30 mg/dL) = low risk; 75–125 nmol/L (30–50 mg/dL) = intermediate risk; ≥125 nmol/L (≈50 mg/dL) = high risk; >180 mg/dL (>430 nmol/L) = very high inherited level

Guideline sourceNational Lipid Association focused update and AHA/ACC statements cited for thresholds and clinical context

Clinical implicationHigher Lp(a) levels may identify populations for targeted risk management and potential future therapies, though impact on outcomes is unestablished

inv-28: hs-CRP threshold (risk enhancing)

hs-CRP threshold (risk-enhancing)≥ 2.0 mg/L (identified as a risk-enhancing factor in ACC/AHA 2019 primary prevention guideline)

ContextListed among lipid/biomarker risk-enhancing factors for clinician-patient risk discussion

Use in assessmentConsidered when refining ASCVD risk in selected patients per guideline recommendations

inv-29: apoB threshold (risk enhancing)

ApoB threshold (risk-enhancing)≥ 130 mg/dL (constitutes a risk-enhancing factor; relative indication when triglycerides ≥200 mg/dL)

Relation to LDL-CLevel ≥130 mg/dL corresponds to LDL-C >160 mg/dL per guideline note

Clinical useApoB measurement reasonable in patients at increased ASCVD risk or with elevated triglycerides

inv-30: Ankle-brachial index threshold

Ankle-brachial index (ABI) threshold< 0.9 (used to identify peripheral artery disease and listed as a risk-enhancing factor)

Guideline contextACC/AHA lists ABI <0.9 among risk-enhancing factors for clinician-patient discussion

ImplicationABI below threshold suggests increased ASCVD risk and may influence management decisions

inv-31: Triglyceride threshold (risk enhancing)

Triglyceride thresholds (risk-enhancing)≥ 175 mg/dL (nonfasting) noted as persistent primary hypertriglyceridemia; ≥200 mg/dL referenced in relation to apoB consideration

Guideline rolePersistent elevated triglycerides are a risk-enhancing factor per ACC/AHA 2019 guidance

Relation to apoBTriglyceride ≥200 mg/dL is a relative indication to measure apoB

inv-32: CLIA standard

CLIA standard for advanced lipoprotein analysisAdvanced lipoprotein analysis must be performed in accordance with the Clinical Laboratory Improvement Amendments (CLIA) 1988 quality standards

Source noteStated in FDA informational section of the policy

ImplicationLaboratories performing advanced lipoprotein testing should meet CLIA quality requirements

Prior Authorization

Prior Authorization and Benefit Verification Required

Before ordering advanced or novel cardiovascular risk tests, verify member benefit coverage and obtain prior authorization when indicated. Coverage decisions depend on federal, state, or contractual benefit terms; code inclusion does not guarantee coverage.

Verify benefit terms and any state or federal coverage requirements before ordering
Listing of a code in this policy does not imply coverage or guarantee claim payment
UnitedHealthcare may use third-party tools (e.g., InterQual) to assist in benefit administration

Denial Risk

Denial Triggers for Unproven / Not Medically Necessary Tests

Tests listed as unproven and not medically necessary (for example, arterial compliance testing, CIMT for screening/management, advanced lipoprotein analysis for routine risk determination, Lp-PLA2, endothelial function assessment, and multi-protein risk-score assays) may be denied. Services added to the unproven/not medically necessary list are subject to denial.

Denial triggers include tests lacking evidence of clinical utility or that are not recommended by guideline bodies
Services newly added to the unproven list (e.g., HDL efflux/LC-MS/MS panels) may be denied until evidence supports clinical utility

Denial Risk

Lp-PLA2: Insufficient Evidence for Routine Coverage

There is insufficient high-quality evidence to support Lp-PLA2 as clinically useful alone or combined with traditional biomarkers to determine CHD risk in asymptomatic individuals; ordering may lead to prior auth requests or denial.

Lp-PLA2 is considered low-quality evidence for routine risk assessment in asymptomatic adults
Additional well-designed trials are needed to establish clinical utility

Denial Risk

Insufficient Evidence May Trigger Denial for Multi-Protein Risk Scores

Multi-protein blood tests reported as a risk score (e.g., HART CADhs, various proteomic panels) currently lack sufficient peer-reviewed evidence demonstrating clinical utility; requests for these tests may be denied or require detailed justification.

Absence of clinical utility studies may trigger denial
If requested, provide peer-reviewed evidence showing outcome benefit and how results will change management

Billing Rule

Coding and Documentation Note

Claims should include applicable procedure and diagnosis codes and supporting documentation. Inclusion of a code in this policy is for reference and does not guarantee coverage or reimbursement.

Listing of a code does not imply that the service is covered or non-covered
Ensure claims include relevant diagnosis codes and clinical documentation to support medical necessity

Documentation Required

CIMT Documentation Considerations

CIMT has heterogeneous measurement methods and provides only modest incremental predictive value beyond traditional risk factors. When CIMT is ordered, document the measurement technique, operator qualifications, and clinical rationale; explain how results will alter management.

Document ultrasound methodology, operator training, and specific rationale for testing
Describe how CIMT results will influence management decisions

Documentation Required

Documentation Note — Tie Orders to Guideline-Based Indications

The evidence base does not support routine clinical utility for many of the listed tests. When ordering any of these assessments, document the guideline-based indication or specific clinical scenario that justifies the test.

Provide guideline-cited indication or specialty consultation notes when applicable
Explain expected impact on patient management and treatment decisions

Documentation Required

Document Guideline-Based Indication

Document guideline-based indications when ordering tests such as Lp(a) or apoB. For tests recommended in specialty guidance (e.g., Lp(a) in certain high-risk or familial scenarios), include the guideline citation and clinical details in the authorization/claim package.

Include relevant guideline references (e.g., AACE/ACE, NLA) in documentation
Specify patient risk factors, family history, or ASCVD status that meet guideline criteria

Note

Documentation and Benefit Verification Reminder

This policy is guidance only — verify federal, state, or contractual benefit requirements before using. UnitedHealthcare reserves the right to modify policies; coverage depends on member benefit terms and applicable law.

Check federal/state/contractual coverage requirements; in a conflict, those requirements govern
Policy updates (e.g., 09/01/2025) may add tests to the unproven list and affect coverage

Step Therapy

Use Standard Risk Assessment First

Use standard risk assessment first: confirm a standard lipid panel and established risk assessment (e.g., Framingham, ASCVD risk estimator) before ordering advanced lipoprotein testing. Advanced testing should be ordered only when initial evaluation is incomplete, equivocal, or when specialty guidance supports further testing.

Obtain a standard fasting lipid panel and document ASCVD risk estimation prior to advanced testing
Consider specialty consultation if advanced testing is being considered for management decisions

Step Therapy

Step — Standard Lipid Panel Before Advanced Testing

Step: obtain a standard lipid panel before considering advanced lipid testing. Advanced tests (apoB, Lp(a), LDL-P) may be considered per guideline-based indications and after initial lipid evaluation; document how results will change management.

Standard lipid panel and risk calculation must be documented before advanced lipoprotein tests are requested
If ordering advanced tests, include rationale and intended management change

Pulse wave velocity (PWV) definitionPulse wave velocity (PWV) is a noninvasive measure of arterial stiffness (arterial compliance) reflecting the speed of the pressure wave along the arterial tree; cfPWV refers to carotid–femoral PWV

Pulse wave analysis (PWA)Pulse wave analysis assesses arterial pressure waveform characteristics (augmentation index, central arterial pressures) from noninvasive measurements

Clinical use and limitsPWV and waveform analysis have been proposed as prognostic indicators for CVD but measurement techniques vary and no gold standard exists for arterial compliance

inv-56: Advanced lipoprotein tests / Lp-PLA2 definition

Advanced lipoprotein analysis definitionAssays that measure lipoprotein subfractions, particle number/sizing, lipoprotein(a), or related enzymes (e.g., Lp-PLA2) proposed to refine cardiovascular risk beyond standard lipid panel

Related tests describedExamples include LDL-P/particle sizing (NMR), vertical auto profile ultracentrifugation, and LC-MS/MS assays of HDL-bound apolipoproteins; multi-protein algorithmic panels also described

Clinical caveatStandardization and demonstrated clinical utility are lacking for many advanced lipoprotein and multi-protein algorithmic tests

inv-57: CIMT progression

CIMT progression definition/interpretationCIMT progression is the change in carotid intima-media thickness over time; a 10 μm/year slower progression was associated with ~9% relative risk reduction for combined CVD endpoints in meta-analysis

Evidence contextMeta-analysis of 119 randomized trials (100,667 participants) related CIMT progression changes to CVD risk reduction estimates

LimitationEffect on outcomes observed with interventions but does not demonstrate that integrating CIMT measurement into clinical care changes management or outcomes

inv-58: Lp(a) elevated

Elevated Lp(a) — variable definitionsElevated Lp(a) is defined variably across studies using population percentiles (e.g., ≥90th percentile) and absolute thresholds (e.g., ≥50 mg/dL); definitions differ by study and assay

ImplicationHeterogeneity in thresholds and assays complicates comparisons and clinical interpretation

Recommendation contextGuideline statements provide suggested cutpoints (see policy thresholds) for clinical consideration

inv-59: Lipoprotein (a) [Lp(a)]

Lipoprotein(a) [Lp(a)] definitionLp(a) is an LDL-like particle with an attached apolipoprotein(a); genetically determined levels are associated with increased risk of major coronary events and CVD

Clinical relevanceHigher Lp(a) levels (e.g., ≥50 mg/dL or ≥90th percentile) are associated with greater risk of MCE and CVD in large cohort and pooled analyses

Use caseMeasurement may help identify individuals for intensified risk management or future therapies but evidence of improved outcomes from testing is not established

inv-60: Lp-PLA2

Lp-PLA2 definitionLipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme measured as mass or activity and investigated as a vascular inflammatory biomarker associated with stroke and cardiovascular risk

Evidence summaryMeta-analyses report modest associations between higher Lp-PLA2 and stroke/CHD risk, but overall evidence quality is low and clinical utility is unproven

Policy conclusionNo conclusions can be drawn on clinical utility of Lp-PLA2 alone or combined with traditional risk assessments for asymptomatic individuals

inv-61: Endothelial function assessment

Endothelial function assessment (PAT, FMD) definitionsPeripheral arterial tonometry (PAT) measures fingertip pulse amplitude response to reactive hyperemia; flow-mediated dilation (FMD) uses brachial artery ultrasound to assess endothelium-dependent dilation

Intended useBoth are noninvasive tests intended to quantify vascular endothelial function and have been proposed as adjuncts to CVD risk assessment

Evidence limitsCohort and clinic studies show inconsistent associations with CVD outcomes and do not establish clinical utility to guide management

inv-62: Reactive hyperemia index (RHI)

Reactive Hyperemia Index (RHI)RHI is an index derived from peripheral arterial tonometry intended to quantify endothelial function via the reactive hyperemia response

Study findingsSome small studies reported correlations with risk scores but RHI failed to reliably predict CAD or revascularization in several analyses

Clinical implicationRHI associations with outcomes are inconsistent and not proven to change clinical decision-making for routine screening

inv-63: Lp(a) risk thresholds

Lp(a) risk thresholds (policy restatement)Policy restates: <75 nmol/L (~30 mg/dL) = low risk; 75–125 nmol/L (30–50 mg/dL) = intermediate; ≥125 nmol/L (~50 mg/dL) = high risk; >180 mg/dL (>430 nmol/L) = very high inherited level

Guideline backingDerived from National Lipid Association and AHA/ACC scientific statements cited in the policy

Clinical noteThresholds used for risk stratification though measurement impact on outcomes remains under study

inv-64: FDA-cleared noninvasive devices

FDA-cleared noninvasive devices (examples)EndoPAT 2000 (FDA 510[k] K032519) cleared as a diagnostic aid for endothelial dysfunction in certain patient populations; SphygmoCor systems cleared for central arterial pressure/waveform analysis

Intended use noteEndoPAT 2000 is not intended as a general population screening test per clearance summary

Device referencesFDA product codes and 510(k) clearances listed for informational purposes only

inv-65: CLIA statement

CLIA statement (policy)Advanced lipoprotein analysis must be performed in accordance with the CLIA 1988 quality standards

Regulatory contextStated in FDA/informational section emphasizing laboratory quality requirements for advanced lipoprotein testing

Practical implicationTests performed without CLIA-compliant labs may not meet policy quality expectations